Sarah Meeks | Vice President Of Business Development

Sarah Meeks, Vice President Of Business Development, MaxCyte

Sarah has over 20 years of senior-level management experience in corporate development in the advanced therapies sector. She is currently Vice President of Business Development, Life Sciences at MaxCyte, Inc. Previously, she was the Vice President of Business Development for Synpromics Ltd. from 2016 until its acquisition in 2019.  From 2013 to 2018, she served as Adjuvant Partner?s Chief Scientific Officer, leading business development and corporate strategy for a number of clients, including large cap pharmaceutical companies, biotechnology companies, technology providers, and major medical centers with a focus on cell and gene therapy. She is on the founding team of Cardiogen Sciences, Inc. (acquired in 2015 by Audentes Therapeutics) and was the Senior Director, Technology Sections at the Alliance for Regenerative Medicine including launching and managing the Gene Therapy Section and the Genome Editing Task Force. Prior to Adjuvant Partners, Sarah held the position of Vice President, Business Development for Orasi Medical, Circle Biologics and BioE.  Sarah holds a Doctorate in molecular biology and bioethics from the University of Minnesota and a Bachelor of Science degree in biochemistry from the University of Wisconsin. From 1995-2004, she completed a post-doctoral fellowship with James M. Wilson, MD, PhD in the University of Pennsylvania?s Human Gene Therapy Program focused on in vivo muscle directed gene therapy as well as served as a licensing manager for the UPENN Center for Technology Transfer and continued her education in the MBA program at the University of Pennsylvania?s Wharton School.    Based in Minneapolis, she enjoys family, gardening, running, hockey and since 2017 has served on the Board of the Minneapolis United Soccer Club, leading fundraising and directing its Advancement Committee.


Day 2: Thursday 20th May 2021 - Gene Therapy @ 16:30

Q&A panel: what’s next in ex-vivo gene therapy and gene editing?

last published: 10/May/21 08:45 GMT

back to speakers